
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 6, 2026, 12:05 PM ET
Wedbush lowers Avalo Therapeutics price target to $20 from $22, maintains Outperform
U.S. listed: $AVTXBiotech · Autoimmune diseasesExecution and funding risks
AVTX Stock Hub: Avalo Therapeutics News, Abdakibart and Clinical Development
Avalo reported $462.8 million of cash and investments, reiterated its 2029 funding outlook and signed a Jefferies agreement for up to $200 million in potential equity sales.
Full research report · PDF
Avalo Therapeutics, Inc. research updated November 5, 2026
18 pages. Q3 results, the LOTUS evidence and Phase 3 plans, funding guidance and the Jefferies sales agreement. Personal use only: redistribution prohibited.
Next company milestone
By year-end 2026 · FDA feedback on the Phase 3 plan
Avalo expects FDA feedback on its proposed abdakibart development plan in hidradenitis suppurativa by year-end 2026 and plans to start the registrational Phase 3 program in H1 2027, with an AVTX-010 IND submission also anticipated in H1 2027. These are company forecasts, not approvals. Q3 2026 results and business update
Investor conferences: management held a fireside chat at the Guggenheim Healthcare Innovation Conference on November 9 at 8:30 a.m. ET; the next is scheduled at the Stifel 2026 Healthcare Conference on November 10 at 2:00 p.m. ET, with a live webcast on the investor website. Conference schedule
AVTX stock at a glance
Close · November 4, 2026
$7.07
Completed Nasdaq regular session before November 5 results.
Price series in PDF, page 2Phase 3 target
H1 2027
Company initiation forecast, reaffirmed November 5; FDA feedback expected by year-end 2026.
SourceATM program
Up to $200m
Jefferies sales agreement of November 5, 2026; sales at the company’s discretion, none disclosed yet.
SourceFunding guidance
Into 2029
Company forecast reaffirmed November 5, 2026; development costs can change.
SourceWhere Avalo Therapeutics stands now
Avalo is a focused clinical-stage IL-1β developer. Abdakibart delivered positive LOTUS HiSCR75 results; the company expects FDA feedback on its Phase 3 plan by year-end 2026 and a Phase 3 start in H1 2027. It reported $462.8 million of cash and investments at September 30, 2026, which it expects to fund operations into 2029, and on November 5 put in place an at-the-market program for up to $200 million of common stock with Jefferies, a source of potential dilution. The unresolved questions concern replication, durability, intellectual property, licensed obligations and eventual commercial positioning. Q3 2026 results · ATM prospectus supplement
Execution and funding. The new Jefferies program allows sales of up to $200 million of stock at market prices; at the $7.32 price used in the prospectus, that would be 27,322,404 shares. The prospectus pro forma count of 81,245,487 uses the September 30 base and excludes 3.9 million shares issued after that date. The November 2 outstanding count was 57,823,083. Phase 3 must reproduce benefit and expand safety exposure. The composition patent expired, additional applications are pending, licensed economics carry obligations, and the HS market is becoming more crowded: on October 22, 2026, AbbVie reported positive Phase 3 data for lutikizumab, ahead of any Avalo Phase 3 start.
The constructive case
LOTUS provides positive randomized evidence at a demanding HS endpoint. The May financing created substantial resources for registration work and a second IL-1β candidate: $462.8 million of cash and investments at September 30, 2026, which the company expects to fund operations into 2029, reducing immediate funding pressure while the lead program advances. AbbVie's positive Phase 3 with lutikizumab, a different IL-1α/β antibody, adds late-stage evidence that IL-1 pathway blockade can improve HS outcomes.
The cautious case
Despite that balance, Avalo set up a $200 million at-the-market program on November 5, 2026, so further equity issuance can follow at the company’s discretion. Phase 3 must reproduce benefit and expand safety exposure. The composition patent expired, additional applications are pending, licensed economics carry obligations, and the HS market is becoming more crowded: on October 22, 2026, AbbVie reported positive Phase 3 data for lutikizumab, ahead of any Avalo Phase 3 start.
Latest Avalo Therapeutics news
Nov 6, 2026
Wedbush lowers Avalo Therapeutics price target to $20 from $22, maintains Outperform
Wedbush reduced its price target on Avalo Therapeutics to $20 from $22. The firm kept its Outperform rating. Analyst action reported by the press; it is the bank's view, not Merlintrader's.
Nov 5, 2026
Avalo Therapeutics files up to $200 million at-the-market stock offering with Jefferies
Avalo Therapeutics entered into an Open Market Sale Agreement with Jefferies LLC dated November 5, 2026, to sell up to $200,000,000 of its common stock from time to time. The stock trades on the Nasdaq Capital Market under the symbol AVTX, with a last reported sale price of $7.07 on November 4, 2026. The agent's commission is up to 3.0% of gross proceeds, and the offering is made under a shelf registration declared effective on January 20, 2026.
Nov 2, 2026
Avalo Therapeutics to participate in upcoming investor conferences
Avalo Therapeutics management will participate in fireside chats at the Guggenheim Healthcare Innovation Conference on November 9, 2026, and the Stifel 2026 Healthcare Conference on November 10, 2026. Live webcasts and replays, when available, can be found under News / Events in the Investors section of the Avalo website. The archived webcast will be available for replay for at least 30 days.
Oct 29, 2026
Trails Edge reports a 5.2% passive stake
A Schedule 13G filed 2026-10-29 reports that Trails Edge beneficially owned 2,803,761 shares, representing 5.2% of the class as of October 22, 2026. This is a dated passive-ownership disclosure, rather than an acquisition announcement or a clinical result. The percentage uses the 53,629,989 shares outstanding on August 3 cited in the filing.
Oct 22, 2026
AbbVie reports Phase 3 INTREPID results in HS
AbbVie reported that lutikizumab, an anti-IL-1α/β antibody, met the HiSCR75 primary endpoint in the Phase 3 INTREPID trial, which randomized about 1,400 patients with HS: 31.4% versus 23.4% for placebo at week 16. AVTX shares closed at $7.45 that session, down about 39% from the previous close of $12.26. As of October 23, 2026, Avalo had not issued a press release or Form 8-K on the data. The read-across concerns a different molecule with a different target profile; abdakibart's own Phase 3 will measure its effect size. · Historical market data · Avalo releases · Avalo filings
Oct 1, 2026
LOTUS efficacy and safety detail
The official congress presentation details the positive HiSCR75 comparison, secondary outcomes and safety through the observed interval. Registration still requires further development.
AVTX stock catalysts and company milestones
- November 5, 2026 — Q3 2026 results reported; cash and investments of $462.8 million, funding guidance into 2029 reaffirmed. Same day: $200 million ATM sales agreement with Jefferies and a new automatic shelf registration. Reported November 5
- November 9, 2026 · 8:30 a.m. ET — Fireside chat at the Guggenheim Healthcare Innovation Conference; webcast on the investor website. Held
- November 10, 2026 · 2:00 p.m. ET — Fireside chat at the Stifel 2026 Healthcare Conference; live webcast. Announced November 2
- By year-end 2026 — FDA feedback expected on the proposed abdakibart Phase 3 development plan in HS. Company guidance, November 5
- H1 2027 — The company targets initiation of the abdakibart registrational HS program and an AVTX-010 IND submission in H1 2027. These are development forecasts, not approvals. Company guidance, reaffirmed November 5
LOTUS results: what the randomized Phase 2 actually showed
LOTUS randomized 253 adults with moderate-to-severe HS in a double-blind, placebo-controlled Phase 2 study. Its primary endpoint was HiSCR75 at week 16. Avalo announced positive topline results on May 5, 2026. The official registry lists the trial as completed, with actual primary completion in February and study completion in March 2026. These dates concern the conduct of the trial; the May announcement was the public results event. Topline announcement · Trial record
The reported week-16 HiSCR75 response rates were 42.2% for the 150 mg group and 42.9% for the 300 mg group, compared with 25.6% for placebo. The reported p values were 0.018 and 0.015, respectively. The combined active groups had a reported response rate of 42.5% with p=0.004. The primary endpoint was met. Those percentages are response rates, while the comparison with placebo describes a smaller percentage-point difference. Results and definitions · Placebo-adjusted differences (16.7 and 17.2 points)
AVTX earnings, cash and investments after the May financing
At September 30, 2026, Avalo reported cash and cash equivalents of $64.988 million, short-term investments of $327.978 million and long-term investments of $69.812 million, together $462.8 million, down from $472.2 million at June 30. Restricted cash of $0.394 million was separate. Net cash used in operating activities was $49.2 million in the first nine months of 2026. Q3 research and development expenses were $15.0 million and general and administrative expenses $8.4 million; the net loss was $18.9 million, or $0.34 per share, versus $30.6 million a year earlier, when a derivative fair-value charge weighed on results. The company expects current resources to fund operations into 2029. Q3 2026 results · Q3 2026 Form 10-Q
The large balance followed the May offering. The initial pricing announcement described a $375 million base transaction. After full exercise of the underwriters' option, gross proceeds were approximately $431.3 million; the quarterly filing reported approximately $404.9 million net. Gross size, net proceeds and the base offering amount are different transaction measures. The net proceeds are the more relevant addition to resources available for development after transaction costs. Offering announcement · Closing update · Quarterly filing
On November 5, 2026, Avalo entered into an Open Market Sale Agreement with Jefferies to sell up to $200 million of common stock from time to time in at-the-market transactions, for a commission of up to 3.0%. Sales are not required and none had been disclosed at filing; the prospectus illustrates 27,322,404 shares at $7.32, which would take the share count from 53,923,083 at September 30 to 81,245,487. The stated use of proceeds is abdakibart and AVTX-010 development, working capital and general corporate purposes. The same day Avalo terminated its June 2025 sales agreement with TD Cowen, a $75 million at-the-market program under which no shares were sold in the first nine months of 2026, and filed a new automatic shelf registration (Form S-3ASR). ATM prospectus supplement · Form 8-K on the new and terminated sales agreements · Shelf registration
Merlintrader Health Score · $AVTX
3.60out of 5
Reassessed November 5, 2026; reviewed November 9, 2026, with scores unchanged, as the November 9 and 10 fireside chats are investor appearances rather than clinical or regulatory events. Weighted calculation: 4.5 × 30% + 3.5 × 30% + 2.5 × 20% + 4.0 × 10% + 3.0 × 10% = 3.60 / 5. Financial and operating resilience over twelve to eighteen months; no price target or investment recommendation.
Red flags
- On November 5, 2026, Avalo entered into an at-the-market program for up to $200 million of common stock with Jefferies; any sales would add shares at market prices.
- Phase 3 must reproduce benefit and expand safety exposure. The composition patent expired, additional applications are pending, licensed economics carry obligations, and the HS market is becoming more crowded: on October 22, 2026, AbbVie reported positive Phase 3 data for lutikizumab, ahead of any Avalo Phase 3 start.
- Company forecasts depend on execution and may change.
- Financial balances are as of the dates shown. Later financing is listed separately.
- Investment involves possible loss of part or all of the capital.
AVTX Stock FAQ: Avalo Therapeutics, Inc. Questions Answered
When will Avalo start Phase 3 for abdakibart?
On November 5, 2026, Avalo said it expects FDA feedback on its proposed development plan by year-end 2026 and plans to initiate its hidradenitis-suppurativa registrational Phase 3 program in H1 2027. Under its November 2 announcement, management held a fireside chat at the Guggenheim conference on November 9 and is scheduled for another at the Stifel conference on November 10 at 2:00 p.m. ET. The trial-start window is company guidance; those conference appearances are not announced clinical readouts or FDA action dates. Phase 3 initiation guidance. November conference schedule.
Is Avalo’s abdakibart FDA approved for hidradenitis suppurativa?
No. Avalo’s November 2, 2026, company description identifies abdakibart, or AVTX-009, as a drug candidate advancing toward registrational Phase 3 development. It is an anti-IL-1β monoclonal antibody studied in hidradenitis suppurativa. Positive Phase 2 LOTUS results support further development but do not constitute marketing approval. Current candidate and development status. Phase 2 results.
How much cash does Avalo have, and what is its runway?
Avalo reported $462.8 million in cash, equivalents and investments at September 30, 2026, and on November 5 said it expects those resources to fund operations into 2029. Cash and equivalents alone were $64.988 million; the aggregate also includes short- and long-term investments. Operating activities used $49.2 million in the first nine months, and the funding outlook depends on the development plan. Aggregate resources and runway guidance. Cash components and operating cash flow.
Could Avalo issue more AVTX shares despite its financing?
Yes. On November 5, 2026, Avalo entered into a sales agreement with Jefferies to sell up to $200 million of common stock in at-the-market transactions; the prospectus illustrates 27,322,404 new shares at the November 2 close of $7.32. Its September-based 81,245,487 pro forma total excludes 3.9 million later issuances. The same day it terminated its earlier $75 million TD Cowen at-the-market program, under which no shares were sold in the first nine months of 2026; convertible preferred shares remain outstanding. Common shares reached 57,823,083 at November 2 after preferred conversions and pre-funded warrant exercises. ATM prospectus supplement and excluded securities. Form 8-K on the sales agreements. Q3 2026 Form 10-Q.
When are Avalo Therapeutics’ next earnings?
Avalo reported Q3 2026 results on November 5, 2026, covering the quarter ended September 30; as of November 9, 2026 it had not announced its next financial-results date. The November 9 and 10 appearances are fireside chats, not earnings releases. Q3 2026 results. Current company release archive. Conference details. Latest quarterly financial update.
What does Avalo Therapeutics do?
Avalo develops therapies targeting the IL-1β pathway in immune-mediated inflammatory diseases. Its November 2, 2026, description identifies lead antibody abdakibart for hidradenitis suppurativa and the earlier long-acting antibody AVTX-010. The company is preparing further clinical development after the lead program’s Phase 2 results. Company and pipeline description.
Did Avalo’s LOTUS trial meet its primary endpoint?
Yes. Avalo reported on May 5, 2026, that LOTUS met the Week 16 HiSCR75 primary endpoint at both doses: response rates were 42.2% and 42.9%, versus 25.6% on placebo (p=0.018 and p=0.015, respectively). Those figures are response rates, rather than forty-plus-percentage-point advantages over placebo. The study supports subsequent pivotal testing. Dose-specific response rates and statistical results.
Is Avalo still recruiting patients into LOTUS?
No. The LOTUS registry update posted April 21, 2026, lists the trial as completed, with 253 actual participants and study completion on March 17. Avalo announced the topline results in May. Its next planned HS development phase is the registrational program, rather than continued recruitment into this completed Phase 2 study. LOTUS status and actual enrollment. May results announcement. Next development program.
Primary sources
- November 5, 2026 — Q3 2026 results: $462.8 million cash and investments, funding into 2029, FDA feedback by year-end
- November 5, 2026 — Form 10-Q for the quarter ended September 30, 2026
- November 5, 2026 — Prospectus supplement: at-the-market program for up to $200 million with Jefferies
- November 5, 2026 — Form 8-K: Jefferies sales agreement entered, TD Cowen sales agreement terminated
- November 5, 2026 — Automatic shelf registration statement (Form S-3ASR)
- November 2, 2026 — Fireside chats at Guggenheim (November 9) and Stifel (November 10)
- Quarterly financial statements and license notes
- Annual business, manufacturing and intellectual-property disclosures
- August corporate update and development guidance
- LOTUS topline results
- Official LOTUS poster
- Official LOTUS oral presentation
- LOTUS trial record
- AVTX-010 program announcement
- May offering terms
- Offering closing update
- AlmataBio milestone buyout
- Employee equity grants
- Randomized anakinra study
- Correction to the anakinra publication
- Early randomized bermekimab study
- Open-label bermekimab study
- Subsequent bermekimab trial and posted results
- AbbVie INTREPID Phase 3 topline results for lutikizumab
- Incyte quarterly report: povorcitinib regulatory status in HS
- September 4 inducement grants to new employees
- Chief Financial Officer Form 4, September 10 transactions
- Chief Financial Officer Form 4, September 16 transactions
- Director Form 4, options in lieu of board fees (1 of 3)
- Director Form 4, options in lieu of board fees (2 of 3)
- Director Form 4, options in lieu of board fees (3 of 3)
- Schedule 13G/A, FMR (July 31, 2026)
- Schedule 13G, Commodore Capital (June 11, 2026)
- Schedule 13G/A, Deep Track Capital (June 30, 2026)
- Schedule 13G, BlackRock (June 30, 2026)
- Schedule 13G/A, RA Capital Management (June 30, 2026)
- Schedule 13G/A, Caligan Partners (June 30, 2026)
- Schedule 13G, State Street (June 30, 2026)
- Schedule 13G/A, Affinity Asset Advisors (June 30, 2026)
- Resale prospectus for 128,189 shares issued to former AlmataBio stockholders
- October 29, 2026 — Trails Edge reports a 5.2% passive stake
- October 22, 2026 — AbbVie's Phase 3 IL-1 data in HS weigh on AVTX
- October 1, 2026 — LOTUS efficacy and safety detail
- September 29, 2026 — Employee grants support the expanding organization
- August 6, 2026 — Resources and the path to Phase 3
- June 16, 2026 — AVTX-010 adds a separate preclinical development path
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $AVTX or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology companies face clinical, safety, regulatory, manufacturing, commercial and financing risks. Trials can fail, adverse effects can limit use, regulatory applications can be delayed or rejected, and an approved medicine may not achieve commercial expectations. Additional borrowing or equity issuance can increase obligations or dilute existing shareholders. Investors can lose part or all of their capital. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



